Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.oxygentapharma.com | |
Market Cap | 130.05 Cr. | |
Enterprise Value(EV) | 184.35 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -4.71 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.93 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | -8.59 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | -4.52 | Calculated using Price: 38.84 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 3.35 Cr. | 33,483,500 Shares |
FaceValue | 10 | |
About Oxygenta Pharmaceutical Ltd. | ||
SS Organics was incorporated in 1990, is a pharmaceutical company involved in the manufacture and marketing of bulk drugs and intermediates. |
1 Day |
|
-2.56% |
1 Week |
|
-4.22% |
1 Month |
|
+30.08% |
3 Month |
|
+12.77% |
6 Month |
|
+47.07% |
1 Year |
|
+20.21% |
2 Year |
|
+57.78% |
5 Year |
|
+301.60% |
10 Year |
|
+423.75% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Return on Capital Employed (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.18 | -50.31 | |
Return on Assets (%) | -33.71 | -29.05 | -29.92 | -25.13 | -17.07 | -29.1 | 11.16 | -1.88 | -27.09 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | -16 | -22 | -27 | -32 | -35 | -41 | -38 | -35 | -46 | -25 | |
Non Curr. Liab. | 18 | 21 | 31 | 31 | 40 | 44 | 54 | 58 | 71 | 55 | |
Curr. Liab. | 16 | 21 | 16 | 18 | 17 | 16 | 18 | 8 | 30 | 33 | |
Minority Int. | |||||||||||
Equity & Liab. | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 64 | |
Non Curr. Assets | 13 | 14 | 13 | 13 | 12 | 12 | 18 | 22 | 29 | 32 | |
Curr. Assets | 5 | 5 | 6 | 4 | 9 | 7 | 16 | 10 | 25 | 32 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 64 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 6 | 12 | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 37 | |
Other Income | 0 | 1 | 1 | 0 | 0 | 0 | 0 | ||||
Total Income | 6 | 12 | 9 | 14 | 21 | 14 | 52 | 61 | 31 | 37 | |
Total Expenditure | -10 | -17 | -13 | -17 | -23 | -22 | -48 | -59 | -38 | -48 | |
PBIDT | -4 | -4 | -4 | -3 | -2 | -8 | 4 | 1 | -7 | -10 | |
Interest | 0 | -1 | -1 | -1 | -1 | -1 | -2 | -1 | -1 | -2 | |
Depreciation | -3 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -3 | |
Taxation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Exceptional Items | 4 | 2 | 1 | -1 | 0 | ||||||
PAT | -6 | -6 | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -16 | |
Adjusted EPS | -6 | -5 | -6 | -4 | -3 | -6 | 3 | 0 | -8 | -6 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -3 | -4 | 1 | 1 | 1 | -8 | -3 | -2 | -2 | -2 | |
Cash Fr. Inv. | -2 | 1 | -2 | -1 | 0 | -1 | -1 | -7 | -5 | -10 | |
Cash Fr. Finan. | 4 | 3 | 1 | 0 | -1 | 8 | 3 | 9 | 6 | 11 | |
Net Change | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fri, 26 Apr 2024
Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015 For The Financial Year Ended 31St March 2024. Please find the enclosed Compliance Certificate under Regulation 7(3) of the SEBI (LODR) Regulations 2015 for the financial year ended 31st March 2024. |
Thu, 25 Apr 2024
Draft Letter of Offer Mark Corporate Advisors Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer to the Equity Shareholders of Oxygenta Pharmaceutical Ltd ("Target Company"). |
Thu, 25 Apr 2024
Compliance Certificate Under Reg.40 (9) Of SEBI (LODR) Regulations 2015 For The Financial Year Ended 31St March 2024. We are enclosing the certificate issued by CS N Vanitha Practicing company Secretary certifying compliance with the requirements of Regulation 40(9) of SEBI (LODR) Regulations 2015. |
Tue, 30 Apr 2024 |
Opening at High |
Making Higher Highs for 2 Days |
High Increase in 1 Month |
High Increase in 3 Months |
High Increase in 6 Months |